CDK2 and breast carcinoma: Thus, it is suggested that the down-regulation of CDK2 in the combined treatment can arrest the TNBC cancer cell cycle and enhance the anti-proliferation effects, imposing a positive effect on the treatments for breast cancer [26,27,28].